CRVO
HEALTHCARECervoMed Inc
$3.83+0.10 (+2.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CRVO Today?
No stock-specific AI insight has been generated for CRVO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.51$11.25
$3.83
Fundamentals
Market Cap$35M
P/E Ratio—
EPS$-2.98
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding9.3M
CRVO News
20 articles- Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy BodiesYahoo Finance·Apr 22, 2026
- CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual MeetingYahoo Finance·Apr 7, 2026
- CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB)Yahoo Finance·Mar 25, 2026
- CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-PathologyYahoo Finance·Mar 19, 2026
- CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Mar 17, 2026
- CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue EstimatesYahoo Finance·Mar 13, 2026
- CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific ConferenceYahoo Finance·Mar 12, 2026
- CervoMed to Participate in Upcoming Investor ConferencesYahoo Finance·Mar 5, 2026
- CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy BodiesYahoo Finance·Mar 4, 2026
- Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards?Yahoo Finance·Mar 3, 2026
- CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral SclerosisYahoo Finance·Feb 18, 2026
- Pleasing Signs As A Number Of Insiders Buy CervoMed StockYahoo Finance·Dec 10, 2025
- CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy BodiesYahoo Finance·Dec 4, 2025
- CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)Yahoo Finance·Dec 2, 2025
- CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) ConferenceYahoo Finance·Nov 24, 2025
- CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Nov 10, 2025
- CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue EstimatesYahoo Finance·Nov 7, 2025
- Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?Yahoo Finance·Nov 7, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$3.73
Day High$0.00
Day Low$0.00
52 Week High$11.25
52 Week Low$3.51
52-Week Range
$3.51$11.25
$3.83
Fundamentals
Market Cap$35M
P/E Ratio—
EPS$-2.98
Dividend Yield—
Dividend / Share—
ROE-0.9%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding9.3M
About CervoMed Inc
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—